The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories. For East and South locations, please visit: corewellhealth.org/labcatalog
The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories. For East and South locations, please visit: corewellhealth.org/labcatalog
An equipment issue resulted in artificially high parathyroid hormone results for some patients from July 31- August 17, 2024. We have repeated testing on the potentially affected samples, corrections were made as necessary, and providers for the impacted patients have been notified.
Review of quality indicator data suggested that issue affecting the results began July 31. Not all patient values were affected, but those that were had artificially high values. The laboratory repeated all PTH testing from this instrument for which remaining sample was available, corrected results, and contacted providers via epic inbox message for CHW providers and other appropriate means for CHW affiliates and external providers whose lab work is performed at CHW in Grand Rapids. Providers of potentially impacted patients whose samples could not be repeated have also been notified.
Beginning August 26, 2024, Corewell Health Laboratories (West and South) will begin updating instrumentation for STI and HPV testing. Aptima collection devices will no longer be available except for pediatric patients under 14 years old.
To order the new swabs:
Please use for pediatric patients or discard any unused APTIMA kits. Please review the link below for images:
Effective August 26, 2024, Corewell Health Laboratories West will be updating their High-Risk HPV testing. The new assay will be performed on the Abbott Alinity m at Corewell Health Reference Laboratory West, Grand Rapids. Testing will now automatically include HPV Genotype results whenever HPV is detected. There will no longer be a separate charge to the patient for HPV Genotype testing.
There will also be an expanded number of High-Risk HPV Genotypes reported:
The new assay is FDA approved for Primary screening in addition to co-testing.
Post hysterectomy vaginal specimens will still be a send out test (LAB1230722).
The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories. For East and South locations, please visit: corewellhealth.org/labcatalog
The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories.
For East and South locations, please visit: corewellhealth.org/labcatalog
The following information was updated in the Lab Catalog.
All changes are for Corewell Health Laboratories West.
Effective May 22, 2024, APTT Direct Thrombin Inhibitor (APTT DTI) will be performed at all Corewell Health West sites including Corewell Health Reference Laboratory and all regional labs (Corewell Health Big Rapids Hospital, Corewell Health Gerber Hospital, Corewell Health Grand Rapids Hospitals (Blodgett Hospital, Butterworth Hospital, Helen DeVos Children’s Hospital), Corewell Health Greenville Hospital, Corewell Health Ludington Hospital, Corewell Health Pennock Hospital, Corewell Health Reed City Hospital, Corewell Health Zeeland Hospital).
The APTT DTI is a clot based assay for monitoring the APTT in patients on direct thrombin inhibitors including Argatroban, Dabigatran, and Bivalrudin. This testing is for inpatient use only. The reference range for this assay is analyzer specific and is listed in the lab catalog (Current reference ranges: Corewell Health Reference Laboratory 23-28 seconds and Regional laboratories 24-34 seconds)
The following information was updated in the Lab Catalog.
All changes are for Corewell Health Laboratories West.
This winter, West Michigan influenza infections peaked in February 2024 and significantly declined throughout March and April 2024. Now with a low prevalence of circulating influenza, using the most sensitive diagnostic test is recommended in order to obtain accurate and actionable results. Influenza antigen testing (e.g. Sofia instrument) is no longer appropriate at this time and Influenza PCR testing should be ordered when clinically indicated.
Low Influenza Prevalence |
High Influenza Prevalence |
|
Recommended Order | Influenza PCR (LAB3255) | Influenza antigen testing (e.g. Sofia instrument) or Influenza PCR (LAB3255) |
More detailed information can be found as published by the CDC: